2015/16 seasonal vaccine effectiveness against hospitalisation with influenza a(H1N1)pdm09 and B among elderly people in Europe

Results from the I-MOVE+ project

I-MOVE+ hospital working group

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We conducted a multicentre test-negative case–control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.

Original languageEnglish
JournalEurosurveillance
Volume22
Issue number30
DOIs
Publication statusPublished - Jul 27 2017

Fingerprint

Human Influenza
Hospitalization
Vaccines
Confidence Intervals
Influenza Vaccines
Lung Diseases
Heart Diseases
Diabetes Mellitus
Lung Neoplasms
Respiratory Tract Infections
Vaccination
Logistic Models
Demography

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health
  • Virology

Cite this

2015/16 seasonal vaccine effectiveness against hospitalisation with influenza a(H1N1)pdm09 and B among elderly people in Europe : Results from the I-MOVE+ project. / I-MOVE+ hospital working group.

In: Eurosurveillance, Vol. 22, No. 30, 27.07.2017.

Research output: Contribution to journalArticle

@article{f316fdf5630c479ba0756e199701ebbc,
title = "2015/16 seasonal vaccine effectiveness against hospitalisation with influenza a(H1N1)pdm09 and B among elderly people in Europe: Results from the I-MOVE+ project",
abstract = "We conducted a multicentre test-negative case–control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42{\%} (95{\%} confidence interval (CI): 22 to 57). It was 59{\%} (95{\%} CI: 23 to 78), 48{\%} (95{\%} CI: 5 to 71), 43{\%} (95{\%} CI: 8 to 65) and 39{\%} (95{\%} CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52{\%} (95{\%} CI: 24 to 70). It was 62{\%} (95{\%} CI: 5 to 85), 60{\%} (95{\%} CI: 18 to 80) and 36{\%} (95{\%} CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.",
author = "{I-MOVE+ hospital working group} and Marc Rondy and A. Larrauri and I. Casado and V. Alfonsi and D. Pitigoi and O. Launay and Syrj{\"a}nen, {R. K.} and G. Gefenaite and A. Machado and Vučina, {V. V.} and Horv{\'a}th, {J. K.} and I. Paradowska-Stankiewicz and Marbus, {S. D.} and A. Gherasim and D{\'i}az-Gonz{\'a}lez, {J. A.} and C. Rizzo and Ivanciuc, {A. E.} and F. Galtier and N. Ikonen and A. Mickiene and V. Gomez and {Kurečić Filipović}, S. and A. Ferenczi and Korcinska, {M. R.} and {Van Gageldonk-Lafeber}, R. and M. Valenciano and Altzibar, {Jone M.} and Arraras, {Ion Garcia} and Gustavo Cilla and Elisa Marco and Matxalen Vidal and Manuel Omenaca and J. Castilla and A. Navascues and C. Ezpeleta and L. Barrado and Ortega, {M. T.} and A. Bella and Castrucci, {M. R.} and S. Puzelli and M. Chironna and C. Germinario and F. Ansaldi and A. Orsi and I. Manini and E. Montomoli and E. Lupulescu and M. Lazar and Cherciu, {C. M.} and Alessia Ranghiasci",
year = "2017",
month = "7",
day = "27",
doi = "10.2807/1560-7917.ES.2017.22.30.30580",
language = "English",
volume = "22",
journal = "Eurosurveillance",
issn = "1560-7917",
publisher = "European Centre for Disease Prevention and Control (ECDC)",
number = "30",

}

TY - JOUR

T1 - 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza a(H1N1)pdm09 and B among elderly people in Europe

T2 - Results from the I-MOVE+ project

AU - I-MOVE+ hospital working group

AU - Rondy, Marc

AU - Larrauri, A.

AU - Casado, I.

AU - Alfonsi, V.

AU - Pitigoi, D.

AU - Launay, O.

AU - Syrjänen, R. K.

AU - Gefenaite, G.

AU - Machado, A.

AU - Vučina, V. V.

AU - Horváth, J. K.

AU - Paradowska-Stankiewicz, I.

AU - Marbus, S. D.

AU - Gherasim, A.

AU - Díaz-González, J. A.

AU - Rizzo, C.

AU - Ivanciuc, A. E.

AU - Galtier, F.

AU - Ikonen, N.

AU - Mickiene, A.

AU - Gomez, V.

AU - Kurečić Filipović, S.

AU - Ferenczi, A.

AU - Korcinska, M. R.

AU - Van Gageldonk-Lafeber, R.

AU - Valenciano, M.

AU - Altzibar, Jone M.

AU - Arraras, Ion Garcia

AU - Cilla, Gustavo

AU - Marco, Elisa

AU - Vidal, Matxalen

AU - Omenaca, Manuel

AU - Castilla, J.

AU - Navascues, A.

AU - Ezpeleta, C.

AU - Barrado, L.

AU - Ortega, M. T.

AU - Bella, A.

AU - Castrucci, M. R.

AU - Puzelli, S.

AU - Chironna, M.

AU - Germinario, C.

AU - Ansaldi, F.

AU - Orsi, A.

AU - Manini, I.

AU - Montomoli, E.

AU - Lupulescu, E.

AU - Lazar, M.

AU - Cherciu, C. M.

AU - Ranghiasci, Alessia

PY - 2017/7/27

Y1 - 2017/7/27

N2 - We conducted a multicentre test-negative case–control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.

AB - We conducted a multicentre test-negative case–control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.

UR - http://www.scopus.com/inward/record.url?scp=85027014121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027014121&partnerID=8YFLogxK

U2 - 10.2807/1560-7917.ES.2017.22.30.30580

DO - 10.2807/1560-7917.ES.2017.22.30.30580

M3 - Article

VL - 22

JO - Eurosurveillance

JF - Eurosurveillance

SN - 1560-7917

IS - 30

ER -